S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Posted on: Monday, 1 December 2008, 14:00 CST
The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr.
"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in
CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated in the development of this condition.
SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in myeloproliferative disorders such as CIMF. It is estimated that approximately 50% of patients with CIMF possess the JAK2 mutation.
In addition to SB1518, S*BIO has a robust proprietary pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor, which is currently in Phase 1 trials in
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. Its second compound, SB1518, has also entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. A third compound, SB1317, is in pre-clinical development.
In line with its vision to be a leading fully-integrated oncology-focused biotech company in
SOURCE S*BIO Pte Ltd
Source: PR Newswire
Related Articles
- TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
- Covance Opens New Clinical Development Offices in Brazil and Mexico
- Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
- Genomic Health Announces Clinical Development Priorities for 2007
- Geron Presents Early Clinical Trial Data for Its Telomerase Inhibitor Cancer Drug
- ArQule Initiates Phase 2 Clinical Development of ARQ 501 for Pancreatic Cancer
- Interim Phase 2 Data Show Sustained Clinical Benefit in Advanced Sarcoma Patients Treated With ARIAD's mTOR Inhibitor, AP23573; Results Highlighted at the AACR-NCI-EORTC News Briefing on New Oncology Drugs
- Pharming Expands Clinical Development of Recombinant Human C1 Inhibitor for New Indications
- Cell Genesys Reports Clinical Data From GVAX(R) Vaccine for Lung Cancer Program
- ARIAD Initiates Phase 2 Clinical Trial of AP23573 in Patients With Recurrent or Persistent Endometrial Cancer; Over 40,000 New Cases of Endometrial Cancer Expected in 2005
 |
 |
User Comments (0)
RSS Feeds